Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Short term Debt (2019 - 2025)

China SXT Pharmaceuticals (SXTC) has 7 years of Short term Debt data on record, last reported at $702184.0 in Q1 2025.

  • For Q1 2025, Short term Debt rose 42.42% year-over-year to $702184.0; the TTM value through Mar 2025 reached $702184.0, up 42.42%, while the annual FY2025 figure was $702184.0, 42.42% up from the prior year.
  • Short term Debt reached $702184.0 in Q1 2025 per SXTC's latest filing, up from $493054.0 in the prior quarter.
  • Across five years, Short term Debt topped out at $12.1 million in Q1 2021 and bottomed at $7863.0 in Q1 2023.
  • Average Short term Debt over 5 years is $2.7 million, with a median of $493054.0 recorded in 2024.
  • Peak YoY movement for Short term Debt: tumbled 99.91% in 2022, then surged 6170.56% in 2024.
  • A 5-year view of Short term Debt shows it stood at $12.1 million in 2021, then crashed by 99.91% to $11404.0 in 2022, then crashed by 31.05% to $7863.0 in 2023, then soared by 6170.56% to $493054.0 in 2024, then surged by 42.42% to $702184.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Short term Debt were $702184.0 in Q1 2025, $493054.0 in Q1 2024, and $7863.0 in Q1 2023.